Hosted on MSN2m
Novo Nordisk Earnings Ease Investor Concerns, Put Focus on New Obesity Drug Trial
Industry observers will now focus on the results of a late-stage trial for Novo Nordisk's experimental obesity medicine, CagriSema, due in December. The new shot combines the medicine in Wegovy and ...
Science Media Centre56m
expert comments on the risks and benefits of tirzepatide following the death of Susan McGowan
Scientists comment on the risks and benefits of tirzepatide (Mounjaro) after a UK death linked to the drug. Prof Naveed Sattar, Professor of Cardiometabolic Medicine/Honorary Consultant, University of ...